SLC5A2 and atherosclerosis: Multiple studies have demonstrated that SGLT2 inhibitors, including dapagliflozin, empagliflozin, canagliflozin, luseogliflzin and ipragliflozin, reduce metabolic indicators to protect from the progression of atherosclerosis (Table 1).